Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

NCT05504707 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT05504707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 1
Overall status
Recruiting
Start date
August 26, 2022
Completion date
October 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, triple negative breast cancer